EGFR and head and neck squamous cell carcinoma: An anti-epidermal growth factor receptor (EGFR) mAb, cetuximab, was approved by the FDA for metastatic colorectal cancer in 2004 and head and neck squamous cell carcinomas (HNSCCs) in 2006 [4].